
Navire Pharma launched with $30mm Series A from parent BridgeBio
Executive Summary
Navire Pharma (small-molecule cancer therapies) has launched with a $30mm Series A investment from parent BridgeBio Pharma, plus IP and a drug development team from MD Anderson Cancer Center.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com